
COVID-19 Vaccination Prevents Development Of Long Covid: BMJ
- byDoctor News Daily Team
- 18 February, 2025
- 0 Comments
- 0 Mins

A recent study published in the British Medical Journal explored the impact of primary COVID-19 vaccination on post-COVID-19 conditions (PCC). The study spanned from December 2020 to February 2022 as part of the Swedish Covid-19 Investigation for Future Insights. This involved 589,722 adults in Sweden, sheds light on the effectiveness of the initial two doses and the first booster shot within the recommended schedule.
PLAY
UNMUTE
:
FULLSCREEN
Out of the 299,692 vaccinated individuals who were infected with COVID-19 during the study, only 0.4% received a diagnosis of PCC during follow-up. This contrasts with the 1.4% of the 290,030 unvaccinated individuals who developed post-COVID conditions. The vaccination strategy, irrespective of the number of doses, demonstrated a substantial reduction in the risk of PCC, with a calculated vaccine effectiveness of 58%.
The breakdown of vaccine effectiveness by dosage found that individuals who received one dose showed 21% effectiveness against PCC, while those with two doses demonstrated a robust 59% reduction in risk. Individuals who received three or more doses experienced an even more significant reduction, with a vaccine effectiveness of 73%.
The study adjusted for various factors, including age, sex, comorbidities, healthcare contacts, socioeconomic factors, and the dominant virus variant at the time of infection. These results underscore the crucial role of primary COVID-19 vaccination in mitigating the population burden of post-COVID conditions.
Despite the positive findings, the study emphasizes the need for ongoing caution and adherence to evidence-based, standard-of-care treatments. While the association between COVID-19 vaccination and reduced PCC risk is strong, researchers call for continued research, especially large-scale clinical trials, to further solidify these conclusions and address any remaining uncertainties.
Reference:
Lundberg-Morris, L., Leach, S., Xu, Y., Martikainen, J., Santosa, A., Gisslén, M., Li, H., Nyberg, F., & Bygdell, M. (2023). Covid-19 vaccine effectiveness against post-covid-19 condition among 589 722 individuals in Sweden: population based cohort study. In BMJ (p. e076990). BMJ. https://doi.org/10.1136/bmj-2023-076990
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
Tags:

Recent News
Normal-Tension Glaucoma Closely Associated With Co...
- 10 October, 2022
Air Pollution Tied To Increased Risk Of Premature...
- 24 May, 2023
NEET PG 2024: NBE Opens Pre-Final Edit Window
- 30 May, 2024
NMC Mulls Over Removal Of Upper Age Cap In MBBS En...
- 30 November, 2021

Daily Newsletter
Get all the top stories from Blogs to keep track.
0 Comments
Post a comment
No comments yet. Be the first to comment!